secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-061992
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio Q3 net loss $7.2M; cash $12.9M; clinical progress on gamma-delta T cell trials
--------------------------------------------------------------------------------

- Net loss $7.2M ($0.23/sh) vs $7.4M ($0.34/sh) in Q3 2022; R&D $3.8M, G&A $3.4M.
- Cash $12.9M at Sep 30, 2023, down from $17.0M at Jun 30, 2023.
- Phase 1 INB-100 dose escalation completed; ASH data presentation Dec 11, 2023.
- Phase 2 INB-400 in newly diagnosed GBM enrollment initiated; SNO poster Nov 17.
- Phase 1 INB-200 updated data at SNO Nov 17; Cohort 3 enrollment ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000095017023061992/0000950170-23-061992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000095017023061992/inab-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer